中南大学学报（医学版）
中南大學學報（醫學版）
중남대학학보（의학판）
JOURNAL OF CENTRAL SOUTH UNIVERSITY (MEDICAL SCIENCES)
2010年
8期
784-791
,共8页
贾海涛%葛峰%卢心鹏%曾慧兰%李丽萍%陈智鹏%卢春花
賈海濤%葛峰%盧心鵬%曾慧蘭%李麗萍%陳智鵬%盧春花
가해도%갈봉%로심붕%증혜란%리려평%진지붕%로춘화
PS-341%多发性骨髓瘤%双向凝胶电泳%质谱%药物靶标
PS-341%多髮性骨髓瘤%雙嚮凝膠電泳%質譜%藥物靶標
PS-341%다발성골수류%쌍향응효전영%질보%약물파표
PS-341%multiple myeloma%2-dimensional gel electrophoresis%mass spectrometry%drug target
目的:比较蛋白酶体抑制剂PS-341处理多发性骨髓瘤细胞U266前后蛋白质组的差异,探究PS-341潜在的药物靶点,为多发性骨髓瘤的临床治疗提供理论依据.方法:用蛋白酶体抑制剂PS-341处理骨髓瘤细胞U266,应用双向凝胶电泳技术分离PS-341处理前后的U266细胞的蛋白质,ImageMaster 2D Platinum图像分析软件识别药物处理前后U266细胞的差异表达蛋白质点,基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)鉴定差异表达的蛋白质.Western印迹法检测差异蛋白质BAG-2在药物处理前后U266细胞中的表达水平.结果:建立了PS-341处理前后U266细胞蛋白质的双向凝胶电泳图谱,找到55个差异表达的蛋白质点,鉴定了31个差异表达的蛋白质,有27个蛋白质在PS-341处理后下调.Western 印迹分析证实BAG-2在药物处理前后U266细胞中的表达水平存在差异.结论:处理后下调的一些蛋白可能是蛋白酶体抑制剂PS-341潜在的药物靶标.
目的:比較蛋白酶體抑製劑PS-341處理多髮性骨髓瘤細胞U266前後蛋白質組的差異,探究PS-341潛在的藥物靶點,為多髮性骨髓瘤的臨床治療提供理論依據.方法:用蛋白酶體抑製劑PS-341處理骨髓瘤細胞U266,應用雙嚮凝膠電泳技術分離PS-341處理前後的U266細胞的蛋白質,ImageMaster 2D Platinum圖像分析軟件識彆藥物處理前後U266細胞的差異錶達蛋白質點,基質輔助激光解吸電離飛行時間質譜(MALDI-TOF-MS)鑒定差異錶達的蛋白質.Western印跡法檢測差異蛋白質BAG-2在藥物處理前後U266細胞中的錶達水平.結果:建立瞭PS-341處理前後U266細胞蛋白質的雙嚮凝膠電泳圖譜,找到55箇差異錶達的蛋白質點,鑒定瞭31箇差異錶達的蛋白質,有27箇蛋白質在PS-341處理後下調.Western 印跡分析證實BAG-2在藥物處理前後U266細胞中的錶達水平存在差異.結論:處理後下調的一些蛋白可能是蛋白酶體抑製劑PS-341潛在的藥物靶標.
목적:비교단백매체억제제PS-341처리다발성골수류세포U266전후단백질조적차이,탐구PS-341잠재적약물파점,위다발성골수류적림상치료제공이론의거.방법:용단백매체억제제PS-341처리골수류세포U266,응용쌍향응효전영기술분리PS-341처리전후적U266세포적단백질,ImageMaster 2D Platinum도상분석연건식별약물처리전후U266세포적차이표체단백질점,기질보조격광해흡전리비행시간질보(MALDI-TOF-MS)감정차이표체적단백질.Western인적법검측차이단백질BAG-2재약물처리전후U266세포중적표체수평.결과:건립료PS-341처리전후U266세포단백질적쌍향응효전영도보,조도55개차이표체적단백질점,감정료31개차이표체적단백질,유27개단백질재PS-341처리후하조.Western 인적분석증실BAG-2재약물처리전후U266세포중적표체수평존재차이.결론:처리후하조적일사단백가능시단백매체억제제PS-341잠재적약물파표.
Objective To compare the proteome difference between multiple myeloma cell line U266 cells treated and untreated with PS-341, to investigate the potential drug targets, and to provide theoretical evidence for clinical therapy of multiple myeloma. Methods Two-dimensional gel electrophoresis (2-DE) was performed to separate proteins from treated and untreated U266 cells with proteasome inhibitor PS-341. ImageMaster 2D Platinum software was used to analyze 2-DE image, and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) was used to identify the differentially expressed proteins. The expression levels of differential protein BAG-2 in the 2 groups of U266 cells lines were detected by Western blot. Results The 2-DE reference pattern of treated and untreated U266 cells with PS-341 was established. A total of 31 differential proteins were identified by MALDI-TOF-MS, 27 of which were down-regulated after PS-341 treatment. The differential expression level of BAG-2 in the 2 groups of U266 cells was confirmed by Western blot. Conclusion Some down-regulated proteins may be the potential drug targets of proteasome inhibitor PS-341.
